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Narrative exposure therapy (NET) is an intervention for trauma spectrum disorders.
Originally developed to treat refugee populations, NET has since been tested for effi-
cacy across different settings. In this review, the NET evidence base is examined
through a retrieval, synthesis and appraisal of randomized controlled trials (RCTs)
published since 2002. Two independent reviewers (S. R. and N. S.) searched online
databases including EMBASE, PsycINFO and PubMed. Twenty-four RCTs were
selected for a meta-analysis of three outcomes: post-traumatic stress disorder
(PTSD) diagnosis and PTSD and depression symptoms. All outcomes were analysed
at short-term (3–4 months), midterm (6–7 months) and long-term (≥12 months) data
points. A random-effects model was applied to yield standardized mean differences
(SMDs) and odds ratios (ORs) as indicators of NET treatment effect. Subgroup ana-
lyses for type of trauma and type of control groups were conducted to examine
potential heterogeneity. For the NET group, moderate effect sizes for PTSD symp-
tom severity were observed at midterm and long term and at midterm for depression
symptom severity. The number of PTSD diagnoses decreased significantly in the
short term for the NET condition, but this was not sustained at the long term. Cau-
tion must be exercised when interpreting these results due to high heterogeneity
estimates and low quality of evidence across trials. Potential small-study effects fur-
ther complicate the interpretation of the findings. Recommendations are made for
augmenting statistical significance research with qualitative analyses of NET efficacy
to better inform clinical practice.
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1 | INTRODUCTION
Narrative exposure therapy (NET; Neuner, Schauer, Roth, &
Elbert, 2002) is an evidence-based approach to treating psychological
manifestations of trauma in survivors (Hamblen et al., 2019; Robjant
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& Fazel, 2010). On the basis of the principles of cognitive behavioural
therapy (CBT), testimony therapy and exposure therapy, NET follows
a manualized treatment protocol that is aimed at constructing a con-
sistent, coherent autobiographical representation of the traumatic
event(s) within the context of a narrative account of one's life. This is
thought to facilitate emotional processing of trauma memories to
bring about improvement in emotional, cognitive and behavioural
symptoms of trauma.
NET was developed specifically for use in low-resource settings
and victims of organized and family violence. It is highly accessible
because it can be delivered by non-mental health professionals fol-
lowing a short training programme using the manual developed by
Schauer, Neuner, and Elbert (2005) and Schauer, Elbert, and
Neuner (2011). A detailed description of the NET procedure can be
found in the treatment manual (Schauer et al., 2005, 2011).
NET has been evaluated using randomized controlled trials (RCTs)
primarily with refugee populations and asylum seekers, wherein the
trauma experienced may be naturally caused or man-made. The focus
in these situations is on the atrocities endured, usually at the hands of
single or multiple perpetrators. Over time, NET has been used to treat
other traumatized populations with/without a perpetrator, with acute
or chronic post-traumatic stress disorder (PTSD) sufferers. This has
been documented in RCTs situated in a range of sociocultural–
economic settings.
International guidelines for PTSD treatment such as the American
Psychological Association (APA), Department of Veterans Affairs and
Department of Defense (VA/DoD), International Society for Trau-
matic Stress Studies (ISTSS) and National Institute for Health and Care
Excellence (NICE) have included NET as part of their recommenda-
tions for intervention.
NICE recommends NET as a first-line treatment option for PTSD
along with CBT, cognitive processing therapy (CPT) and prolonged
exposure (PE). On the contrary, APA guidelines published a condi-
tional recommendation for NET, claiming the evidence was insuffi-
cient for a strong recommendation (APA, 2017). Strong
recommendations were made for CBT, CPT and PE. Similarly,
VA/DoD found PE and eye movement desensitization and
reprocessing (EMDR) to have the strongest evidence base, whereas
NET was found to have ‘sufficient’ evidence for a strong recommen-
dation (VA/DoD, 2017). ISTSS also provided a standard recommenda-
tion for NET (Berliner et al., 2019) and a strong recommendation for
CPT, EMDR and trauma-focused CBT. As such, the evidence base for
CBT, CPT, PE and EMDR appears to be stronger when compared with
NET. A systematic evaluation of the NET evidence base is essential to
better inform clinical and practice guidelines regarding its efficacy.
1.1 | Rationale for review
By publishing data about NET efficacy, one can advocate for its wide-
spread implementation in low-resource settings to alleviate symp-
toms. Narrative reviews of NET efficacy have found NET favourable
to controlled comparisons in reducing traumatic stress in a range of
socio-economic and cultural contexts including low dropouts and
sustained improvements over time (McPherson, 2012; Robjant &
Fazel, 2010). In one meta-analysis of NET efficacy, authors found a
medium effect size (g = 0.63) for PTSD symptom reduction post-
intervention (Gwozdziewycz & Mehl-Madrona, 2013). This estimate
was interpreted as evidence of NET efficacy, although it is not clear
how the average effect size was calculated in terms of follow-up time
points. The control groups used for comparisons with NET are varying
and not restricted to ‘bona fide’ or active treatments, that is, treat-
ments that were intended to be ‘therapeutic’ (Wampold & Imel, 2015).
For example, RCTs used wait-list groups, no-treatment groups and
supportive counselling as controlled comparisons to NET. Importantly,
most reviews have not critically appraised the quality of the evidence,
which makes these findings inconclusive regarding NET's true treat-
ment efficacy.
NET trials have been included in large meta-analytic studies of a
range of psychological therapies for traumatic stress (Bisson, Roberts,
Andrew, Cooper, & Lewis, 2013; Patel, Kellezi, & Williams, 2014). In
these reviews, the methodological rigour of the included NET trials
was questioned. Further, both reviews included only a handful of NET
trials each (N = 07, Bisson et al., 2013; N = 04, Patel et al., 2014), and
since their publication, several recent trials investigating NET efficacy
have been published. This suggests a need to conduct a comprehen-
sive, up-to-date quality appraisal of the NET evidence base to inform
researchers and practitioners.
Only one other comparable meta-analytic review was identified
at the time of this review (Lely, Smid, Jongedijk, Knipscheer, &
Kleber, 2019). The authors of this review concluded that despite
methodological weakness in the included trials, there is empirical sup-
port for NET as a trauma intervention. However, at least seven publi-
shed RCTs of NET efficacy have not been included in the review, and
the authors have used ‘last follow-up’ as the uniform follow-up time
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• Narrative exposure therapy (NET) significantly alleviates
post-traumatic stress disorder (PTSD) symptoms at mid-
term and long-term time points compared with control
interventions.
• Diagnostic status of PTSD is statistically improved by
NET only at the short-term and midterm time points.
• Depression symptoms are significantly lower for NET
groups only at the midterm time point.
• Most trials are underpowered and are highly heteroge-
neous across outcomes and time points. Quality of evi-
dence for NET efficacy is weak due to high risk of bias
across domains.
• Caution is advised when interpreting pooled intervention
effects from randomized controlled trials to determine
the efficacy of NET in clinical settings.
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point. NET trials vary significantly in their measurement of outcomes,
especially concerning data points. In the Lely, Smid, et al. (2019) meta-
analysis, this ranged from 9–52 weeks. They also do not include PTSD
diagnostic status (i.e., meeting the criteria for a diagnosis of PTSD) as
a measured outcome, which could potentially be an important consid-
eration when making a recommendation for clinical efficacy.
In this paper, a meta-analysis of NET efficacy is attempted using
all available data from NET clinical trials published to date. The term
‘efficacy’ is used unequivocally throughout this paper as NET RCTs
have predominantly evaluated the intervention under ideal and con-
trolled circumstances (Roland & Torgerson, 1998). This is differenti-
ated from evaluations of ‘effectiveness’ (a measure of intervention
benefit under ‘real-world’ clinical conditions). Of note, some of the
included trials as well as a previously published meta-analytic review
(Lely, Smid, et al., 2019) have used the term ‘effectiveness’ inter-
changeable with ‘efficacy’, although the design of the trial is in line
with an efficacy evaluation.
For the meta-analysis, the pooled intervention effect of NET will
be estimated against controlled comparisons on outcomes of PTSD
(symptom severity and diagnostic status) and depression symptom
severity. Due consideration will also be given to issues of heterogene-
ity and methodological quality of the included trials.
2 | OBJECTIVES
The objective was to evaluate the efficacy of the NET evidence base
for the treatment of trauma-related psychopathology on outcomes of
PTSD and depression across different sociocultural contexts and
trauma exposure.
3 | METHODS
Search results that fulfilled the selection criteria were scrutinized at
the abstract and full-text stage independently by two reviewers (the
first and second authors: S. R. and N. S.). Appropriate data were
extracted independently by both reviewers, and disputes, if any, were
resolved by the third author, N. H. The risk of bias was assessed by
S. R. and N. S. in accordance to version 1.0 of the Cochrane risk of
bias tool for randomized trials (Higgins & Green, 2011).
3.1 | Inclusion criteria
3.1.1 | Types of studies
Original RCTs using NET (or an adaptation of NET) were included.
Inclusion criteria for the trial population were individuals with a his-
tory of exposure to trauma and reporting PTSD outcome measures
(diagnostic status and/or symptom severity) following such exposure.
No restrictions were placed based on the type of trauma experienced
by the population. The search was not limited to RCTs with
participants over 18 years of age. Instead, we chose to exclude studies
that used the version of NET adapted for children below the age of
18 years: KIDNET (Onyut et al., 2005). From an initial scoping review
of the NET literature, it was anticipated that some trials may include a
combination of both adults and underage (<18 years) participants,
especially in the case of refugees and asylum seekers. Further,
KIDNET was developed and tested for efficacy merely 3 years since
the first publication of NET (Neuner et al., 2002), which would make it
the preferred choice for studies strictly recruiting participants under
18 years of age. By not placing an explicit age restriction and instead
using the KIDNET filter, we aimed to include all available data publi-
shed on NET trials conducted with adult participants.
Studies from any part of the world implementing any control
comparisons were included. No restrictions were placed on the num-
ber of control comparisons. Outcome measures included PTSD (scales
or diagnostic interviews) and depression symptoms.
3.1.2 | Timing of outcome assessment
End point assessments were used. NET does not have a fixed number
of sessions or intervention duration, and we anticipated some varia-
tions in timings of outcome assessments across studies. As a result,
we estimated effects at (a) short term (3–4 months), (b) midterm (6–-
7 months) and (c) long term (12 months or above).
3.2 | Search strategy
The local databases searched were PubMed, CINHAL, PsycINFO,
Medline, Cochrane Library and Embase. The search strategy for
PubMed is presented inTable A1 as an example. Additionally, the orig-
inal authors of NET were contacted and asked to provide a full publi-
cation list of NET research. The date last searched is 8 December
2019.
3.3 | Selection and screening
Two authors (S. R. and N. S.) independently screened all titles and
abstracts. Full-text articles were reviewed for inclusion, and data were
extracted independently by S. R. and N. S. Cohen's kappa statistic was
calculated to indicate inter-rater agreement at the title and abstract
screening stages (Cohen, 1960). Kappa values were interpreted using
Landis and Koch's (1977) guidelines. Included publications were
extracted for relevant data, and disagreements were resolved by the
third author (N. H.).
3.4 | Risk of bias
Two authors (S. R. and N. S.) separately assessed the risk of bias by
using criteria according to the Cochrane Collaboration's risk of bias
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tool (Higgins & Green, 2011). At the time of completion of this review,
there was no mandate to use the updated version (RoB 2.0; Sterne
et al., 2019), and it was still being pilot tested by the Cochrane Review
teams (Cochrane Library, 2019). Additionally, assessment issues and
therapist qualifications were included as domains of risk. For assess-
ment issues, criteria for low risk of bias included the use of valid and
reliable measures or the use of translated measures with sufficient
psychometric properties. In the absence of such information for trans-
lated versions, the risk was deemed unclear. When trials failed to
report whether measures were valid and reliable, or when there was a
lack of clarity regarding attempts to translate and back-translate stan-
dardized measures, the trials were considered to have a high risk of
bias. For therapist qualifications, trials that reported details of the
therapist's NET training and qualifications qualified for a low risk of
bias. If such information was found insufficient or lacking, the trials
were rated as having an unclear risk of bias. If the intervention was
delivered by untrained individuals with a lack of relevant qualifica-
tions, or if the study did not report any information at all, it was rated
as having a high risk of bias.
Funnel plots were examined for comparisons with 10 or more tri-
als to indicate publication bias in line with the rule of thumb rec-
ommended by the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins et al., 2019). Disagreements were resolved by
the third author, N. H.
3.5 | Data synthesis
A random-effects (RE) model was used to calculate the standardized
mean differences (SMDs) and 95% confidence intervals (CIs) for con-
tinuous outcomes. The odds ratio (OR) and 95% CIs were calculated
by using an RE model for dichotomous variables. When trials reported
multiple treatment arms, the non-NET active treatment arm was
treated as a control group and was combined with the non-active
treatment control group (such as wait-list or no-treatment controls) to
generate pooled mean and standard deviation (SD) values. Study
authors were contacted for missing data, such as means and SDs. If
these data could not be obtained, those trials were excluded from the
meta-analysis. The desktop version of Review Manager (RevMan, ver-
sion 5.3) was used for data analysis (RevMan, 2014).
3.6 | Assessment of heterogeneity
Visual inspection of graphs, a Mantel–Haenszel χ2 statistic and I2 sta-
tistic was used to test for heterogeneity. An I2 estimate ≥50% accom-
panied by a statistically significant χ2 statistic was interpreted as
evidence of substantial levels of heterogeneity.
3.7 | Subgroup analysis
From a clinical perspective, combining studies that varied by the type
of trauma experienced by the participants and the type of control
conditions used in the analysis could impact the findings. To investi-
gate the influence of such variability, two subgroup analyses were
conducted. The first subgroup analysis was based on the type of con-
trol, that is, active treatment versus no treatment. Type of traumatic
event was also used for a subgroup analysis between trauma with a
perpetrator (such as war trauma, combat trauma, abuse and violence
and torture) and trauma without a perpetrator (such as natural disas-
ters and occupational trauma). Age is also a potential effect modifier.
If enough studies (N = 10; Higgins et al., 2019) with participants below
18 years of age are found, a subgroup analysis based on age will be
performed.
3.8 | Sensitivity analysis
The effects of excluding trials with a high risk of bias or those that
appeared to be outliers upon a visual inspection of forest plots were
conducted as part of the meta-analysis. When the removal of these
studies did not change the direction or significance of the treatment
effect, they were included in the final analysis.
4 | RESULTS
A total of 306 results were retrieved from the database search, and
110 were chosen after screening titles. Inter-rater agreement for
screening titles was substantial (k = 0.676). Six studies were added
from the NET reference database received from NET authors. After
discarding duplicates (N = 76), the abstracts of 40 records were
screened for inclusion. Fifteen studies were excluded due to the fol-
lowing reasons: (a) conference abstracts (02), (b) study protocols (03),
(c) dissertation copy of included study (01), (d) KIDNET studies (03),
(e) non-RCTs (02), (f) non-experimental study (01), (g) NET was not
the intervention in question (02) and (h) PTSD not measured as an
outcome (01). Inter-rater agreement for screening abstracts was
almost perfect (k = 0.896).
Twenty-six full-text studies were retrieved for full-text review.
Two studies had to be excluded at this stage; one study did not meet
the randomization criteria (Crombach & Siehl, 2018), and the authors
of the other study were unable to provide the required data for the
meta-analysis (Hinsberger et al., 2017). Twenty-four trials were
included in the final meta-analysis.
The PRISMA flow diagram in Figure B1 illustrates the selection of
the studies included in the review.
4.1 | Included studies
A total of 1,391 participants were recorded in the trials included,
with sample sizes ranging from 18 to 277. Studies were conducted
across the world, including countries in Africa, Europe, Asia and
North America. Most participants were survivors of war trauma and
organized and/or personal violence, and in a few studies,
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participants were survivors of natural disasters. The mean age of
the participants across trials ranged from 17 to 70 years. NET was
administered in the intervention arm in 18 studies. Four trials used
an adaptation of NET known as the Narrative Exposure Therapy for
Forensic Offender Rehabilitation (FORNET; Hecker, Hermenau,
Crombach, & Elbert, 2015) meant for persons with a history of per-
petrated violence. In two trials, different versions of brief NET were
used. In one trial, a combination of NET and interpersonal psycho-
therapy (IPT) was used. The most common control condition was
wait-list controls (WLC; 10 trials; see Table A2). An average of 7.58
sessions of NET therapy was delivered across all 24 included trials
with a range of 14.2. All studies provided details of attrition during
treatment except one (Morath, Moreno-Villanueva, et al., 2014). The
rate of attrition varied from 0% to 38.64% , with a mean attrition
rate of 7.43% during treatment. Studies that reported dropout data
highlighted the sensitive nature of refugee and asylum status (such
as camp closures, receiving asylum, disappearance and transfers) as
common reasons for dropout. Other reasons included a lack of
motivation, trust, and psychosocial problems. One study with abuse
victims reported emotional suffering over treatment as a reason for
dropout (Orang et al., 2018).
Twenty-three trials reported the severity of PTSD symptoms as
one of the primary outcomes, and 13 trials reported PTSD diagnos-
tic status as a measured outcome. The Clinician-Administered PTSD
Scale (CAPS; American Psychiatric Association, 1994) was used to
diagnose and assess the frequency and severity of PTSD symptoms
in nine trials. Other measures that were used included the PTSD
Symptom Scale Interview (PSS-I; Foa, Riggs, Dancu, &
Rothbaum, 1993; Foa & Tolin, 2000), Composite International Diag-
nostic Interview (CIDI; World Health Organization, 1990), Post-
Traumatic Stress Diagnostic Scale (PDS; Foa, Cashman, Jaycox, &
Perry, 1997), Scale of Post-traumatic Stress Symptoms (SPTSS), Har-
vard Trauma Questionnaire (HTQ; Arabic version; Shoeb, Weinstein,
& Mollica, 2007) and Impact of Events Scale-Revised (IES-R; Weiss
& Marmar, 1997).
Depression symptom severity was most commonly measured in
trials along with PTSD symptoms (N = 18). Hamilton Depression Rating
Scale (HAM-D; Hamilton, 1960, 1967), Hospital Anxiety and Depres-
sion Scale (HADS; Zigmond & Snaith, 1983), Patient Health
Questionnaire-9 (PHQ-9; Spitzer, Kroenke, & Williams, 1999), Beck
Depression Inventory (BDI; Beck, Steer, & Brown, 1996), Self-
Reporting Questionnaire 20 (SRQ-20; Harding et al., 1980), Mini-
International Neuropsychiatric Interview (M.I.N.I.; Sheehan et al., 1998)
and Hopkins Symptoms Checklist (HSCL; Derogatis, Lipman, Rickels,
Uhlenhuth, & Covi, 1974) were all used to measure this outcome in the
form of self-report as well as structured interviews.
For a detailed description of the studies, please refer toTable A2.
4.2 | Risk of bias
Figure B2 depicts the risk of bias assessment for the trials included in
the meta-analysis.
4.2.1 | Random sequence generation
Recognized randomization procedures were used in 15 out of 24 trials,
and these trials were rated as low risk. Nine trials were judged as
reporting unclear randomization techniques. Some of these trials did
not report the randomization technique, whereas others used tech-
niques that may or may not ensure complete randomization
(e.g., randomizing only a section of eligible participants and not the
others and using restricted randomization, which could introduce
selection bias). In two of these trials, assessment of baseline outcomes
was used for the assignment of participants to treatment and control
groups, which suggests that the sequence generation may not have
been random (Crombach & Elbert, 2015; Hermenau, Hecker, Schaal,
Maedl, & Elbert, 2013).
4.2.2 | Allocation concealment
Only two studies were judged to report adequate information about
allocation concealment. The remaining 22 trials did not indicate infor-
mation about allocation concealment. Most of these studies reported
that groups did not significantly differ at baseline on outcomes or
demographics, which could indicate adequate randomization. These
studies were categorized as having unclear risk.
4.2.3 | Blinding of participants and personnel
Only one study reported blinding of participants to decrease the likeli-
hood of further unblinding of outcome assessment. However, there
was no mention of blinding personnel, as this is not possible in an
RCT using a psychological intervention such as NET. This led to the
trial being rated as unclear for performance bias (Jacob, Neuner,
Maedl, Schaal, & Elbert, 2014). The remaining 23 trials were rated as
having a high risk of performance bias.
4.2.4 | Blinding of outcome assessment
Seven trials were judged to be at high risk for detection bias due to
not implementing appropriate blinding while assessing outcomes
post-intervention and at follow-up. In four of these trials, patients
accidentally revealed their treatment condition to the assessors. In
two trials, the lead author, who was also one of the therapists,
assessed outcomes, which placed these trials at high risk for detection
bias. Four trials did not provide adequate information or suggested
plausible, accidental unblinding and were rated as having unclear risk.
The remaining studies were rated as having a low risk of bias.
4.2.5 | Incomplete outcome data
Four trials were at high risk for attrition bias due to analysing only
treatment completers. In one trial that analysed only treatment
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completers, authors found that demographics and study variables did
not significantly predict treatment completers or dropouts in a logistic
regression analysis (Orang et al., 2018). Further, the type of therapy
did not significantly predict dropouts either. In a second trial, missing
data from dropouts were replaced by estimation with a restricted
maximum likelihood procedure, and no significant differences were
found before and after data were replaced (Alghamdi, Hunt, &
Thomas, 2015). Thus, the authors analysed only treatment com-
pleters. The authors in both trials did not publish these results in the
final report. Therefore, these trials have been classified as having
unclear risk. The remaining trials were classified as low risk due to
either reporting no dropout or using some form of intention-to-treat
(ITT) methods to account for missing data.
4.2.6 | Selective reporting
Nine trials were judged as low risk for selective reporting, as all
primary and secondary outcomes reported in the protocol were
matched with those reported in the final publication. A further six
trials with published protocols were judged as having unclear risk
due to not reporting secondary outcomes mentioned in the proto-
col in the final publication. Other trials judged as unclear risk were
due to the lack of a protocol available. Two studies were catego-
rized as high risk for selective reporting due to not reporting pri-
mary outcomes indicated in the protocol. Only four out of eight
comparisons had 10 or more trials contributing to the analysis
(PTSD symptoms at short term and midterm and depression symp-
toms at short term and midterm). A visual examination of the fun-
nel plots (see Figure B3) for these comparisons did not clearly
indicate asymmetry.
4.2.7 | Other sources of bias
4.2.7.1 Therapist qualification
Seven trials reported that the interventions were delivered by clinical
psychologists/counsellors with NET and trauma experience. Nine tri-
als reported that the therapist was a PhD/graduate student or thera-
pist who had explicit NET training per the manual. These studies were
classified as low risk. Two trials did not specify the training or manual
adherence procedures of their therapists (clinical psychologists and
clinical psychology doctoral students). Hence, these trials have been
classified as unclear in terms of risk. Three trials used trained ‘lay
counsellors’ to deliver therapy. In these trials, the qualifications of the
therapists were unclear. One trial used trained final year undergradu-
ate psychology students, whereas another used clinical psychology
undergraduate degree holders who were trained in NET. These trials
were classified as having unclear risk because NET is a manualized
technique that does not require clinical or medical qualifications for
its administration (Schauer et al., 2005). However, the lack of graduate
qualification/healthcare training does not allow for these trials to be
completely devoid of risk of bias.
4.2.7.2 Assessment issues
Only five studies used valid and reliable measures for the assessment
of outcomes. These trials have been categorized as low risk. Eleven
trials performed real-time translation and back-translation of outcome
measures to capture the symptoms of PTSD and depression, which
are primary outcomes of interest to this review. No information was
provided about the psychometric properties of the translated mea-
sure. Further, translations and back translations achieve linguistic
equivalence, which often subsumes the importance of cultural mean-
ingfulness and appropriateness to the context. One trial used struc-
tured interviews using interpreters to measure outcomes (Neuner
et al., 2010). In these cases, one cannot rule out the risk of the asses-
sor's influence in achieving the desired outcome. Therefore, these tri-
als were classified as having an unclear risk of bias. A further eight
trials did not report information regarding the translation of English
language outcomes or the use of valid instruments to measure out-
comes, which suggest these trials are at a high risk of bias. Figure B4
depicts the risk of bias summary for the trials included.
4.3 | Effects of intervention
The main comparison was NET versus control for the treatment of
PTSD and depressive symptoms and PTSD diagnostic status.
4.3.1 | Comparison: NET versus any control
Twenty-four full-text studies were included in the meta-analysis. Due
to different scales of assessment being used to measure the outcomes
discussed, results were combined as SMDs. All 24 included studies
contributed to the above comparison. This comparison had nine ana-
lyses, and the results have been summarized inTable A3.
4.3.1.1 PTSD diagnostic status
4.3.1.1.1 Short term (3–4 months). Four studies relevant to this out-
come were identified (total N = 173; see Figure B5). There was a sig-
nificant effect of NET intervention on diagnosis compared with
control, with an OR of 0.28 (95% CI 0.12 to 0.66, Z = 2.89, p = .004).
Heterogeneity was low at 3%.
4.3.1.1.2 Midterm (6–7 months). Four studies contributed to this out-
come (total N = 150, see Figure B6). There was evidence of a signifi-
cant effect of intervention on diagnostic status compared with control
(OR 0.26; 95% CI 0.13 to 0.55, Z = 3.59, p = .0003). Heterogeneity
was 0%.
4.3.1.1.3 Long term (≥12 months). Three relevant studies with a total
of 190 participants were identified (see Figure B7). NET did not signif-
icantly outperform controls in this analysis (OR 0.68; 95% CI 0.16 to
2.87, Z = 0.51, p = .60). Further, significantly high levels of heteroge-
neity were found (χ2 = 9.96; df = 2.0; p = .0071; I2 = 80%). One study
that appeared to be an outlier (Neuner, Schauer, Klaschik, Karunakara,
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& Elbert, 2004) was removed from the analysis, and although this
reduced the heterogeneity estimates to 0% (χ2 = 0.45, df = 1 [p = .45];
I2 = 0%), the direction or significance of the effect was not altered,
and the study was retained in the final analysis.
4.1.1.2 PTSD symptoms
4.1.1.2.1 Short term (3–4 months). Fifteen relevant studies contributed
to this outcome, with a total of 813 participants (see Figure B8). Small
effect size evidence that NET was significantly different in its effects
compared with controlled comparisons was found (SMD −0.30, 95%
CI −0.49 to −0.11, Z = 3.05, p = .002). Moderate but non-significant
heterogeneity was found (χ2 = 21.62, df = 14 [p = .09]; I2 = 35%). A
sensitivity analysis was conducted in which an outlier study was
removed from the analysis (Adenauer et al., 2011). This study also had
a high risk of bias in three domains This reduced the heterogeneity
(I2 = 6%) and did not alter the significance of treatment effect (SMD
−0.21, 95% CI −0.37 to −0.06, Z = 2.78, p = .005). Therefore, it was
considered in the analysis due to not altering the
direction/significance of the treatment effect.
4.1.1.2.2 Midterm (6–7 months). Fourteen trials across 13 studies rele-
vant to this outcome (total n = 763; see Figure B9) were identified.
NET emerged significantly superior to controlled interventions with a
medium effect size (SMD −0.45, 95% CI −0.68 to −0.23, Z = 4.01,
p < .0001). Moderate yet significant levels of heterogeneity were
found (χ2 = 23.29, df = 13 [p = .04]; I2 = 44%). A visual inspection of
the forest plot suggested that point estimates across trials were not
drastically different. The removal of the high risk of bias trials (with
three or more domains showing a high risk) slightly increased hetero-
geneity estimates (χ2 = 18.22, df = 10 [p = .05]; I2 = 45%) but did not
alter the direction or significance of treatment effect. As a result, they
were considered in the final analysis.
4.1.1.2.3 Long term (≥12 months). Seven relevant studies contributed
to this outcome with a total of 302 participants (see Figure B10). NET
emerged superior to control interventions (SMD −0.49, 95% CI −0.8
to −0.18, Z = 3.06, p = .002) with a medium effect size. Moderate, sta-
tistically non-significant heterogeneity was noted among studies
(χ2 = 9.19, df = 6 [p = .16]; I2 = 35%). Two outliers were identified
using the forest plot (Köbach, Schaal, Hecker, & Elbert, 2017; Neuner
et al., 2004), and their removal lowered heterogeneity estimates
(χ2 = 1.25, df = 4 [p = .87]; I2 = 0%). The removal of these trials did not
alter the significance or direction of the effect (SMD −0.28, 95% CI
−0.55 to 0.01, Z = 2.03, p = .04) and hence will be considered for the
final analysis.
4.1.1.3 Depression
4.1.1.3.1 Short term (3–4 months). For this outcome, 11 relevant stud-
ies were found with a total of 444 participants. NET emerged statisti-
cally superior to controlled comparisons, albeit with a small effect size
(SMD −0.32, 95% CI −0.61 to −0.03, Z = 2.15, p = .03). Further, this
outcome had high, significant levels of heterogeneity (χ2 = 20.89;
df = 10.0; p = 0.02; I2 = 52%). One study that appeared to be an
outlier based on visual inspection of the forest plot was removed from
the analysis (Adenauer et al., 2011). This reduced the level of hetero-
geneity (χ2 = 12.25, df = 9 [p = .20]; I2 = 27%). However, the treat-
ment effect emerged non-significant (SMD −0.23, 95% CI −0.46 to
0.01, Z = 1.88, p = .06) and lowered the effect size value further. This
trial also had a high risk of bias in three domains. As a result, this study
will be excluded from the final analysis, and the final forest plot will
contain 10 studies (see Figure B11).
4.1.1.3.2 Midterm (6–7 months). Eleven trials across 10 studies involv-
ing 424 participants were included in this comparison (see Figure
B12). NET was significantly superior to controls (SMD −0.49, 95% CI
−0.79 to −0.20, Z = 3.25, p = .001) with a medium effect size. This
outcome had significant levels of heterogeneity (χ2 = 20.64, df = 10
[p = .02]; I2 = 52%). Three trials were identified as outliers (Bichescu,
Neuner, Schauer, and Elbert, 2007; Pabst et al., 2014; Schaal, Elbert,
& Neuner, 2009). Removing these trials reduced heterogeneity
(χ2 = 6.54, df = 7 [p = .48]; I2 = 0%) and did not alter the significance
or direction of treatment effect (SMD −0.43, 95% CI −0.65 to −0.22,
Z = 3.91, p < .001). Hence, they will be used for the final analysis.
4.1.1.3.3 Long term (≥12 months). Six studies with a total of 273 partici-
pants were included in this outcome. There was a significant treat-
ment effect of NET (SMD −0.37, 95% CI −0.75 to 0.01, Z = 1.92,
p = .05). Heterogeneity was found to be high (χ2 = 10.04, df = 5
[p = .07]; I2 = 50%). A visual inspection of the forest plot identified an
outlier (Köbach et al., 2017). A sensitivity analysis with its removal
reduced heterogeneity (χ2 = 1.66, df = 4 [p = .80]; I2 = 0%). With its
removal, the test for the overall treatment effect became non-
significant (SMD −0.19, 95% CI −0.46 to 0.09, Z = 1.34, p = .18). As a
result, this study was removed from the final analysis, which con-
tained five studies (see Figure B13).
4.3.2 | Subgroup analysis
4.3.2.1 Types of controls
To account for the clinical heterogeneity in the type of control condi-
tions that NET was compared with across trials, a subgroup analysis
of active controls (e.g., other psychological therapies, treatment-as-
usual and psychoeducation) versus inactive control (e.g., no treatment
and WLC) was performed at the three time points for PTSD and
depression symptoms.
Subgroup differences were significant only for PTSD symptom
severity at the short term. Categorizing studies by type of interven-
tion, NET demonstrated a difference between subgroups (p = .04) and
reduced heterogeneity in the no intervention group (N = 407,
I2 = 23%). In this group, there was evidence of a medium effect of
NET (SMD −0.44, 95% CI −0.68 to −0.21, p = .0002). In contrast, the
active intervention group demonstrated a lack of effect (N = 454,
SMD −0.07, 95% CI −0.34 to 0.20, p = .62). Within the active inter-
vention subgroup, substantial, non-significant heterogeneity estimates
were revealed (p = .12, I2 = 40%).
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For depression symptoms at midterm, NET significantly out-
performed active interventions (SMD −0.50, 95% CI −0.84 to −0.16,
p = .004), whereas a non-significant overall effect was found when
compared with the no intervention subgroup. However, the subgroup
differences did not reach statistical significance (p = .27). In this analy-
sis, the active intervention group was characterized by significant het-
erogeneity (χ2 = 21.28; df = 9; p = .0; I2 = 58%), and the no
intervention subgroup consisted of only three studies.
Subgroup differences for PTSD and depressive symptoms were
not significant at any other time point based on the type of control
groups (seeTable A4).
4.3.2.2 Type of trauma
For the purpose of this analysis, types of trauma varied between
trauma with a perpetrator and trauma without a perpetrator in trials,
and these categories were compared in a subgroup analysis. Trauma
without a perpetrator included singular events such as natural disas-
ters or trauma induced by occupational stress. Trauma with a perpe-
trator consisted of either repetitive or consistent trauma or threat of
trauma such as war, combat, torture and abuse.
Subgroup differences for PTSD and depressive symptoms were
not significant at the short-term and midterm time points based on
the type of trauma. PTSD and depressive symptoms in the long term
could not be analysed for subgroup differences based on trauma due
to a lack of relevant trials in the simple trauma subgroup (see
Table A5).
4.3.2.3 Age
There was insufficient data to perform a subgroup analysis based on
age of participants.
5 | DISCUSSION
5.1 | Summary of main results
A meta-analysis of NET treatment effect on PTSD diagnosis and
symptoms and depressive symptoms yielded partial evidence of effi-
cacy. The effect size of treatment on PTSD symptoms is small in the
short term (SMD = −0.30, 95% CI −0.49 to −0.11) but medium at the
midterm (SMD = −0.45, 95% CI −0.68 to −0.23) and long term
(SMD = −0.49, 95% CI −0.80 to −0.18), suggesting sustainable treat-
ment gains. These findings are consistent with other narrative ana-
lyses of NET efficacy (Mundt, Wünsche, Heinz, & Pross, 2014).
Conversely, a statistically significant effect of NET was found on PTSD
diagnostic status in the short-term and midterm time points, but these
effects were not sustained at long-term follow-up. It is important to
note that the outcome at long term was characterized by very high
heterogeneity estimates. Further, only a small number of trials contrib-
uted to the analyses for PTSD diagnostic status at all time points
(N < 5), which impacts the findings for this outcome. When RE models
are used, including a substantial number of studies is necessary in
order to make reliable inferences, especially in the presence of high
between-study heterogeneity (Guolo & Varin, 2017; Seide, Röver, &
Friede, 2019). This significantly impacts the findings for this outcome.
In terms of depression symptoms, NET emerged statistically supe-
rior to controlled comparisons only at midterm with a medium effect
size (SMD = −0.49, 95% CI −0.79 to −0.20). Lely, Smid, et al. (2019)
found that NET outperformed non-active controls with medium-to-
large effect sizes (g = 0.79) for depression symptoms. In our study,
this was not reflected in the subgroup analysis for types of control for
depression symptoms at any time point. However, in line with their
overall conclusion, it appears that NET is relatively less effective in
treating depressive symptomatology.
Subgroup analyses for type of controls emerged significant only
for PTSD symptoms at the short term, with NET performing better
than no intervention controls, when compared with active interven-
tions. Within the active intervention subgroup, a non-significant over-
all effect of NET was found (p = .62). Although this could imply that
NET does not outperform active interventions as efficaciously as
WLC and no-treatment controls, the wide 95% CIs of the point esti-
mate (−0.07, 95% CI –0.34 to 0.20) suggest caution in the interpreta-
tion of the summary statistic for this subgroup. The relatively high yet
non-significant heterogeneity estimates (I2 = 40%, p = .12) also sug-
gest that within the active intervention group, there is potential for
further subgroup analysis based on the type of the controls. Subgroup
differences were not statistically significant for either outcome at any
other time point. Lely, Smid, et al. (2019) found that NET significantly
outperformed only non-active controls for both PTSD and depression
symptoms. However, they do not specify the follow-up timings for
controlled comparisons in their study, thereby limiting the comparabil-
ity of these findings. Regarding type of trauma, the lack of subgroup
differences suggest that NET is similarly efficacious across a range of
trauma populations.
Conclusions about the evidence of treatment effect (especially
when applied to clinical practice) must be made with caution due to
high heterogeneity estimates when the data were statistically pooled.
An exploration of heterogeneity using the visual inspection method
allowed us to identify outliers, and the removal of these trials did not
reduce heterogeneity in all trials. This is especially true in the case of
PTSD symptoms at 6 months (significant effect) and PTSD diagnosis
at 9–12 months (non-significant effect).
5.2 | Quality of evidence
In a systematic review by Gwozdziewycz and Mehl-Madrona (2013),
the authors noted that the trials included in the review were validly
designed and executed. However, we found varying degrees of bias
across the included trials. Unclear randomization procedures were
identified in a handful of trials, thereby potentially compromising the
quality of these trials. The risk of allocation bias was mostly unclear
across the review, due to a lack of adequate detail provided by study
authors to make a definitive judgement. Almost all trials were consid-
ered to have a high risk of performance bias. This was due to treat-
ment allegiance to a single psychotherapeutic intervention (NET),
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making the blinding of personnel impossible due to the nature of the
intervention. However, while blinding of participants could be possi-
ble to some extent, the extensive use of WLC and no-treatment con-
trol groups made this impossible in most trials. The risk of bias
regarding outcome assessments suggested that most studies used
self-report or assisted-report psychometric scales, translated and
back-translated from English. No information was provided about the
psychometric validity and reliability of the translated tool, and one
cannot rule out the effect of interpreters or translators in achieving
desired outcomes during assessments. As a result, several trials were
judged as having an unclear risk of bias.
Studies used varying assessment methods such as scales of
assessment, the language of administration, use of interpreters and
diagnostic interviews versus self-report versus assisted report. This
could potentially explain high heterogeneity among trials. Additionally,
many RCTs did not report methodological aspects such as information
on blinding, allocation and use of valid and reliable outcome measures
clearly, which led to several studies being judged as having an unclear
risk of bias.
There were other methodological concerns to be considered.
Most of the trials reported WLC in addition to no-treatment condi-
tions. Only a handful of studies used other active, bona fide inter-
ventions as controlled comparisons. As in Lely, Smid, et al. (2019),
NET performed better against non-active comparators, but the dif-
ference was not statistically significant. The use of WLC in anxiety
disorders research has been criticized (Patterson, Boyle, Kivlenieks,
& Van Ameringen, 2016). Studies have identified ethical and human-
itarian issues of delaying treatment to individuals who are undergo-
ing acute distress or may be at risk for self-harm and suicide
(Devilly & McFarlane, 2009). Additionally, the use of WLC may be
associated with other methodological concerns related to increased
risk of bias (Mohr et al., 2009) and larger effect sizes for the psy-
chotherapy group (Furukawa et al., 2014). Specially with regard to
PTSD research, a meta-analysis of 20 studies and 418 participants
demonstrated small-to-medium effect sizes (g = 0.34) for WLC,
whereas bona fide trauma-focused treatments yielded very large
effect sizes (g = 1.5; Devilly & McFarlane, 2009). Similar findings
were demonstrated in a review of WLC effect sizes in social anxiety
disorder research (Steinert, Stadter, Stark, & Leichsenring, 2017). In
agreement with a narrative review of NET efficacy (Robjant &
Fazel, 2010), it is problematic to draw conclusions regarding NET's
superior efficacy compared with other trauma-focused treatments
due to lack of sufficient RCTs using such active treatments
as controls.
5.3 | Limitations of the current review
The first limitation of this meta-analysis is that a protocol was not reg-
istered a priori. Preregistered protocols ensure methodological rigour
and commitment, and the lack of a published protocol before the
commencement of data collection and analysis is acknowledged as a
shortcoming of this paper.
The risk of bias assessments were conducted with the Cochrane
Collaboration's risk of bias tool available at the time of analysis
(Higgins & Green, 2011). Since that time, a new version of the tool
(RoB 2.0) was released by the Cochrane Collaboration (Sterne
et al., 2019). The updated tool is not yet available on the RevMan
software and is currently being piloted by the Cochrane Review team.
Future studies may employ RoB 2.0 to perform a comparable analysis
of internal validity and quality appraisal.
Another limitation is that several trials used adaptations of NET
ranging from NET specifically targeted to forensic offenders
(FORNET) to brief versions of NET. No subgroup comparisons were
planned and therefore conducted between RCTs that used NET and
those with adapted NET. As such, targeted analyses of studies using
specific adaptations will provide conclusive data of their efficacy, but
due to the small number of trials reporting homogenous adaptations,
it was not possible to determine whether NET can be successfully
adapted to reduce symptomatology.
Other limitations of the paper are related to the included studies
themselves. Some RCTs had very small sample sizes (in some cases
below 10), with only two notably well-powered studies. Further, only
four comparisons had over 10 studies contributing to the analysis. This
raises the issue of small-study effects (i.e., the overestimation of inter-
vention effects in trials with small to moderate trial size). Underpow-
ered studies tend to show exaggerated treatment effects when
compared with well-powered studies, as well as contributing to higher
heterogeneity estimates. (Turner, Bird, & Higgins, 2013). Further, one
of the possible causes of small-study effects could be publication bias
(Higgins et al., 2019). Only published trials were included in this analy-
sis, and the number of trials included in each comparison was low. It
could be argued that with the inclusion of unpublished trials, smaller
estimates of treatment effects for NET would emerge. Only four com-
parisons were eligible for funnel plot analyses, and a visual inspection
did not reveal clear evidence of asymmetry. However, it is well known
that asymmetry interpretations are subjective and may be caused by
other issues such as methodological heterogeneity (Sedgwick, 2013). It
must also be noted that tests for publication bias using funnel plots
(such as the Egger's test) are less reliable when small trials dominate the
meta-analysis, which is the current case (Egger, Davey Smith,
Schneider, & Minder, 1997). Therefore, the issue of small-study effects
complicates the reliability of the NET evidence base considerably.
5.4 | Strengths and comparisons to other reviews
An attempt was made to access and include all relevant trials through
the search strategy. Although it is possible that we may have missed
some published or unpublished material, our correspondence with the
NET authors suggests that our review is the most comprehensive and
complete analysis to date.
In addition to the trials included in Lely, Smid, et al. (2019), we
have reviewed a further eight trials as well as analysed PTSD diag-
nostic status, which makes our findings more comprehensive and
more up-to-date. In terms of quality appraisal, we find our ratings
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to be more conservative with several trials being rated as having a
high risk of bias on domains rated by Lely, Smid, et al. (2019) as
unclear. Subgroup analyses conducted in our review also attempted
to address the issue of potential clinical heterogeneity in combining
different trauma groups and trials using varied control groups
together. Our results suggest that other sources of heterogeneity
must be explored to account for the high estimates in the analyses
across comparisons. Lely, Smid, et al. (2019) concluded that despite
methodological issues and high heterogeneity estimates, NET trials
provide evidence of favourable treatment efficacy. However, we
recommend greater caution in the interpretation of the meta-
analytic findings in our comprehensive and more conservative over-
view of NET efficacy.
6 | CONCLUSION
6.1 | Implications for practice
Currently, low-quality evidence indicates the efficacy of NET over
both active and non-active psychotherapeutic control treatments in
primarily decreasing PTSD symptom severity and, to a small extent,
depression severity. The data were significantly heterogeneous
across most outcomes measured. Further, there was no impact of
the type of trauma or type of controls on treatment effect, which
leaves heterogeneity estimates unexplained. Low dropout rates from
therapy are an indication of NET's acceptability and feasibility with
sensitive populations. NET has been tested with a range of trauma
groups, that is, with and without perpetrators. Although NET shows
promise with both groups, the evidence base for NET is most
strongly suited to the group it was originally intended for, that is,
victims of war and organized violence. Although this suggests that
NET may be suitable for diverse trauma groups, there is not enough
data to draw conclusions regarding NET's applicability when there is
no perpetrator involved. The highly heterogeneous treatment groups
(in terms of trauma history, risk of a future threat and sociocultural–
economic settings) further confound the pooling of effects.
NET is currently recommended by a range of clinical guidelines
for PTSD treatment including APA, NICE, VA/DoD and ISTSS.
Regarding clinical efficacy, it is important to consider findings from
reviews and meta-analyses. This involves considering the quality of
the evidence base as opposed to focusing on data from individual
RCTs or using narrative summaries. Although these trials may have
found promising effects, the small sample sizes and methodological
issues warrant caution when using the findings to inform policies
and guidelines. Further, clinical guidelines have questioned the appli-
cability of NET to non-refugee trauma populations. Because a
majority of the trials so far have used NET with refugees and asy-
lum seekers, we highlight this as a further limitation of the evidence
base. In future research with NET, diverse trauma exposure across a
range of sociocultural settings must be considered, specifically with
non-refugee populations, to warrant its recommendation as a PTSD
treatment approach.
6.2 | Implications for research
The NET evidence base includes RCTs conducted in diverse settings.
As previously discussed, Mundt et al. (2014) critiqued the NET evi-
dence base as being inapplicable to low- and middle-income countries
(LMIC) as well as being unable to address as aspects of psychosocial
well-being. In their review of interventions for torture survivors, Patel
et al. (2014) raise similar concerns about the need to consider legal,
contextual and psychosocial factors in the delivery of trauma
interventions.
From a research perspective, RCTs of short-term interventions
(of which NET is an example) have long since been criticized for
underestimating or altogether missing out on some of the most crucial
aspects of psychotherapy such as its self-correcting nature, addressing
multiple, interacting problems and co-morbidities and the-
rapist/practitioner-related moderators that impact outcomes and
treatment effects (Fensterheim & Raw, 1996; Persons &
Silberschatz, 1998; Seligman, 1995; Shean, 2014). However, as Ras-
mussen (2014) argues, RCT findings cannot be expected to address all
aspects of psychosocial well-being but can augment components of
care packages intended to effect recovery at multiple levels of well-
being. The larger issue concerns the need for empirical health systems
research, in that the scope of NET research needs to be widened to
include the socio-economic, political and cultural contexts of the local
communities they are intended to be implemented in. Holistic treat-
ment and care systems must be evaluated for efficacy as opposed to a
single component, that is, the intervention. This is especially applica-
ble to NET research, a technique whose basis, that is, storytelling, is
woven into the unique sociocultural fabric of diverse societies.
Mechanisms of change is an important, under-researched area
when it comes to NET inquiry. A few included trials have isolated neu-
robiological and molecular correlates of recovery when NET is used
(Adenauer et al., 2011; Morath, Gola, et al., 2014; Morath, Moreno-
Villanueva, et al., 2014). Additionally, psychological mechanisms of
change can add rich detail to bettering intervention protocols. A rigor-
ous, in-depth qualitative analysis of the narratives or final testimony
could provide new insight into change by identifying and isolating
indicators of recovery or deterioration in accordance to treatment
protocols in the manual (Schauer et al., 2005, 2011). This evidence
adds depth to statistical data, as testimonies are largely personal
accounts of change and are bound to integrate the psychosocial, polit-
ical, economic and cultural context of the treatment setting.
Homogenous, well-powered trials using uniform methodological
design as well as comparable outcome assessments (e.g., measures
and follow-up time) are needed to substantiate NET's spot among
active trauma interventions. When complemented by deeper, qualita-
tive analyses of mechanisms of change, NET's evidence base can be
strengthened to reveal its true effect across trauma populations.
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APPENDIX A.
TABLE A1 Search strategy example: PubMed
1. narrative exposure* [Title/Abstract] OR ‘narrative exposure therapy’ [Title/Abstract] OR ‘NET’ [Title/Abstract] OR narrative therapy [Text Word]
Articles retrieved: 106,999
2. ‘ptsd’ [Text Word] OR posttraumatic stress* [Text Word] OR post-traumatic stress* [Text Word] OR ‘psychological trauma’ [Text Word]
Articles retrieved: 48,966
3. randomi?ed controlled trial [PublicationType] OR ‘RCT’ [Title/Abstract] OR controlled clinical trial [PublicationType] OR randomi?ed [Title/Abstract]
OR randomly [Title/Abstract] OR trial [Title/Abstract]
Articles retrieved: 1,098,239
4. 1 AND 2 AND 3
Articles retrieved: 64
TABLE A2 Characteristics of included studies
Study Population Location Intervention Controls
Psychological
outcomes





Alghamdi, et al. (2015) Firefighters Saudi
Arabia









Young refugees Iraq NET (N = 20) Emotional freedom technique










Bichescu et al. (2007) Former Romanian political
detainees
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Former child soldiers Uganda NET (N = 29) Academic catch-up (N = 28),





















































Jacob et al. (2014) Genocide victims (widows and
orphans)
Rwanda NET + IPT
(N = 38)
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TABLE A2 (Continued)








Older adults with trauma
exposure (political, sexual
and childhood trauma)




Morath, Gola, et al.
(2014)
African and Middle Eastern
refugees









African and Middle Eastern
refugees
Germany NET (N = 19) WLC (N = 19) PTSD diagnosis
PTSD symptoms
Neuner et al. (2004) Sudanese refugees Uganda NET (N = 17) Supportive counselling




























Orang et al. (2018) Intimate partner violence
survivors
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TABLE A2 (Continued)
Study Population Location Intervention Controls
Psychological
outcomes
Pabst et al. (2014) Physical/sexual abuse/assault
survivors








































Earthquake survivors China NET and
Brief NET
(N = 20)











Abbreviations: CBT, cognitive behavioural therapy; FORNET, narrative exposure therapy for forensic offender rehabilitation; IPT, interpersonal psychother-
apy; N, number of participants randomized; NET, narrative exposure therapy; PTSD, post-traumatic stress disorder; WLC, wait-list controls.
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TABLE A3 Summary of findings
Outcomes
Treatment effect Heterogeneity
SMD/OR 95% CI Z p N χ2 df p I2 (%)
PTSD Diagnosis (ST) 0.28 (OR) 0.12 to 0.66 2.89 .004 173 3.09 3 .38 3
Diagnosis (MT) 0.26 (OR) 0.13 to 0.55 3.59 .0003 150 1.75 3 .63 0
Diagnosis (LT) 0.68 (OR) 0.16 to 2.87 0.52 .60 190 9.96 2 .007 80
Symptoms (ST) −0.30 (SMD) −0.49 to −0.11 3.05 .002 813 21.62 14 .09 35
Symptoms (MT) −0.45 (SMD) −0.68 to −0.23 4.01 <.0001 763 23.29 13 .04 44
Symptoms (LT) −0.49 (SMD) −0.80 to −0.18 3.06 .002 302 9.19 5 .16 35
Depression Symptoms (ST) −0.23 (SMD) −0.46 to 0.01 1.88 .06 425 12.25 9 .20 27
Symptoms (MT) −0.49 (SMD) −0.79 to −0.20 3.25 .001 424 20.64 10 .02 52
Symptoms (LT) −0.19 (SMD) −0.46 to 0.09 1.34 .18 224 1.66 4 .80 0
Abbreviations: CI, confidence interval; LT, long term; MT, midterm; OR, odds ratio; PTSD, post-traumatic stress disorder; SMD, standardized mean differ-
ence; ST, short term; Z, test of overall effect.




differencesActive intervention No intervention







454 −0.07 −0.34 to
0.20
0.49 .62 407 −0.44 −0.68 to
−0.21
3.68 .0002 4.12 1 .04 75.7
Midterm 608 −0.41 −0.74 to
−0.08
2.43 .02 320 −0.46 −0.69 to
−0.23
3.91 <.0001 0.05 1 .82 0
Long
term
241 −0.42 −0.88 to
0.04
1.8 .07 380 −0.44 −0.78 to
−0.10





199 −0.15 −0.51 to
0.20
0.85 .40 293 −0.34 −0.73 to
0.05
1.71 .09 0.48 1 .49 0
Midterm 354 −0.50 −0.84 to
−0.16
2.90 .004 127 −0.23 −0.58 to
0.12
1.28 .20 1.21 1 .27 17.1
Long
term
213 −0.19 −0.57 to
0.19
0.98 .33 96 −0.35 −1.12 to
0.42
0.88 .38 0.13 1 .72 0
Abbreviations: CI, confidence interval; long term, ≥12 months; midterm, 6–7 months; PTSD, post-traumatic stress disorder; short term, 3–4 months; SMD,
standardized mean difference; Z, test of overall effect.
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differencesWith a perpetrator Without a perpetrator







732 −3.39 −5.92 to
−0.86
2.63 .009 81 −1.84 −5.82 to
2.13
0.91 .36 0.42 1 .52 0
Midterm 741 −0.47 −0.70 to
−0.23
3.91 <.0001 28 −0.31 −1.06 to
0.43
0.83 .41 0.15 1 .70 0
Long
term







363 −0.39 −0.73 to
−0.06
2.29 .02 81 −0.09 −0.79 to
0.62
0.24 .81 0.59 1 .44 0
Midterm 402 −0.53 −0.85 to
−0.21
3.17 .002 28 −0.13 −0.88 to
0.61
0.35 .72 0.93 1 .33 0
Long
term
289 −0.28 −0.53 to
−0.03
2.23 .03 NA
Abbreviations: CI, confidence interval; long term, ≥12 months; midterm, 6–7 months; NA, not applicable; PTSD, post-traumatic stress disorder; short term,
3–4 months; SMD, standardized mean difference; Z, test of overall effect.
F IGURE B1 PRISMA study flow diagram
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F IGURE B2 Risk of bias graph [Colour figure
can be viewed at wileyonlinelibrary.com]
F IGURE B3 Funnel plots of comparison: narrative exposure therapy versus controls (all): (a) post-traumatic stress disorder (PTSD) symptoms
(short term), (b) PTSD symptoms (midterm), (c) depression symptoms (short term) and (d) depression symptoms (midterm). Abbreviation: SMD,
standardized mean difference [Colour figure can be viewed at wileyonlinelibrary.com]
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F IGURE B4 Risk of bias summary [Colour figure can be viewed at wileyonlinelibrary.com]
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F IGURE B6 Forest plot: Post-traumatic
stress disorder diagnosis (midterm).
Abbreviations: CI, confidence interval; NET,
narrative exposure therapy [Colour figure
can be viewed at wileyonlinelibrary.com]
F IGURE B5 Forest plot: Post-
traumatic stress disorder diagnosis (short
term). Abbreviations: CI, confidence
interval; NET, narrative exposure therapy
[Colour figure can be viewed at
wileyonlinelibrary.com]
F IGURE B7 Forest plot: Post-
traumatic stress disorder diagnosis (long
term). Abbreviations: CI, confidence
interval; NET, narrative exposure therapy
[Colour figure can be viewed at
wileyonlinelibrary.com]
F IGURE B8 Forest plot: Post-
traumatic stress disorder symptoms (short
term). Abbreviations: CI, confidence
interval; NET, narrative exposure therapy
[Colour figure can be viewed at
wileyonlinelibrary.com]
F IGURE B9 Forest plot: Post-
traumatic stress disorder symptoms
(midterm). Abbreviations: CI, confidence
interval; NET, narrative exposure therapy
[Colour figure can be viewed at
wileyonlinelibrary.com]
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F IGURE B10 Forest plot: Post-
traumatic stress disorder symptoms (long
term). Abbreviations: CI, confidence
interval; NET, narrative exposure therapy
[Colour figure can be viewed at
wileyonlinelibrary.com]
F IGURE B11 Forest plot:
Depression symptoms (short term).
Abbreviations: CI, confidence interval;
NET, narrative exposure therapy [Colour
figure can be viewed at
wileyonlinelibrary.com]
F IGURE B12 Forest plot:
Depression symptoms (midterm).
Abbreviations: CI, confidence interval;
NET, narrative exposure therapy [Colour
figure can be viewed at
wileyonlinelibrary.com]
F IGURE B13 Forest plot:
Depression symptoms (long term).
Abbreviations: CI, confidence interval;
NET, narrative exposure therapy [Colour
figure can be viewed at
wileyonlinelibrary.com]
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